Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis - The

The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry - Meegdes - 2022 - International Journal

PDF] Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer

Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies

Cancers, Free Full-Text

CDK4/6 inhibition in breast cancer: current practice and future directions - Sonia Pernas, Sara M. Tolaney, Eric P. Winer, Shom Goel, 2018

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2 -negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis - The Lancet Oncology

Targeting HER2-positive breast cancer: advances and future directions

Cureus, Role of Cyclin-Dependent Kinase 4/6 in Metastatic Breast Cancer: Real-World Data From a Tertiary Care Institute in Eastern India

PDF) Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer